| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| RNA, Long Noncoding | 6 | 2019 | 408 | 3.09 | Why? |
| Biomarkers, Tumor | 12 | 2019 | 1314 | 1.97 | Why? |
| Gene Expression Regulation, Neoplastic | 12 | 2019 | 1014 | 1.43 | Why? |
| Melanoma | 8 | 2019 | 1229 | 1.07 | Why? |
| B7-H1 Antigen | 3 | 2017 | 541 | 1.03 | Why? |
| Triple Negative Breast Neoplasms | 3 | 2018 | 92 | 0.91 | Why? |
| Adrenergic beta-2 Receptor Antagonists | 1 | 2020 | 16 | 0.88 | Why? |
| Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 43 | 0.87 | Why? |
| Receptors, Adrenergic, beta-2 | 1 | 2020 | 32 | 0.86 | Why? |
| Tumor Microenvironment | 3 | 2019 | 264 | 0.86 | Why? |
| Cyclooxygenase 2 | 2 | 2018 | 129 | 0.82 | Why? |
| Carcinogenesis | 2 | 2019 | 236 | 0.81 | Why? |
| Genes, Homeobox | 1 | 2018 | 2 | 0.78 | Why? |
| Osteosarcoma | 1 | 2019 | 83 | 0.73 | Why? |
| Salivary Gland Neoplasms | 1 | 2018 | 25 | 0.72 | Why? |
| Receptors, Progesterone | 1 | 2018 | 76 | 0.72 | Why? |
| Estrogen Receptor alpha | 1 | 2018 | 40 | 0.71 | Why? |
| Histocytological Preparation Techniques | 1 | 2017 | 17 | 0.71 | Why? |
| Receptor Protein-Tyrosine Kinases | 2 | 2017 | 243 | 0.70 | Why? |
| RNA, Untranslated | 1 | 2019 | 140 | 0.70 | Why? |
| Neoplasms | 12 | 2021 | 17251 | 0.67 | Why? |
| Gene Rearrangement | 1 | 2017 | 84 | 0.67 | Why? |
| In Situ Hybridization, Fluorescence | 1 | 2017 | 207 | 0.62 | Why? |
| Immunohistochemistry | 9 | 2018 | 2275 | 0.60 | Why? |
| Receptors, Androgen | 1 | 2018 | 212 | 0.60 | Why? |
| Molecular Targeted Therapy | 3 | 2020 | 1579 | 0.54 | Why? |
| Carcinoma | 1 | 2017 | 256 | 0.53 | Why? |
| MicroRNAs | 4 | 2019 | 1787 | 0.50 | Why? |
| Neoplasm Proteins | 1 | 2018 | 501 | 0.48 | Why? |
| Lymphocytes, Tumor-Infiltrating | 3 | 2017 | 130 | 0.48 | Why? |
| Ovarian Neoplasms | 2 | 2017 | 465 | 0.48 | Why? |
| Magnetic Resonance Imaging | 6 | 2018 | 6551 | 0.47 | Why? |
| Lung Neoplasms | 5 | 2019 | 3228 | 0.44 | Why? |
| Breast Neoplasms | 7 | 2018 | 3633 | 0.44 | Why? |
| Skin Neoplasms | 4 | 2018 | 1679 | 0.44 | Why? |
| Lymphatic Metastasis | 3 | 2018 | 537 | 0.43 | Why? |
| Adenocarcinoma | 2 | 2017 | 651 | 0.42 | Why? |
| Carcinoma, Squamous Cell | 5 | 2018 | 902 | 0.41 | Why? |
| Rectal Neoplasms | 3 | 2018 | 278 | 0.39 | Why? |
| Neoplasm Metastasis | 5 | 2019 | 682 | 0.38 | Why? |
| Mastocytoma | 1 | 2007 | 2 | 0.36 | Why? |
| Cell Proliferation | 8 | 2019 | 1973 | 0.36 | Why? |
| Proto-Oncogene Proteins B-raf | 3 | 2019 | 179 | 0.34 | Why? |
| Carcinoma, Papillary | 2 | 2017 | 76 | 0.32 | Why? |
| Carcinoma, Neuroendocrine | 1 | 2007 | 57 | 0.32 | Why? |
| Cytodiagnosis | 2 | 2017 | 104 | 0.32 | Why? |
| Biopsy, Fine-Needle | 3 | 2017 | 274 | 0.31 | Why? |
| Environmental Monitoring | 1 | 2018 | 3143 | 0.31 | Why? |
| Drug Resistance, Neoplasm | 3 | 2018 | 447 | 0.30 | Why? |
| Receptors, Estrogen | 2 | 2019 | 171 | 0.28 | Why? |
| Neoplastic Stem Cells | 2 | 2017 | 120 | 0.28 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.27 | Why? |
| Neoadjuvant Therapy | 2 | 2018 | 554 | 0.27 | Why? |
| Cell Line, Tumor | 8 | 2019 | 3608 | 0.25 | Why? |
| Mutation | 6 | 2019 | 12376 | 0.25 | Why? |
| Neoplasm Staging | 4 | 2017 | 1999 | 0.25 | Why? |
| Contrast Media | 3 | 2018 | 1011 | 0.25 | Why? |
| Immunotherapy | 5 | 2021 | 2421 | 0.24 | Why? |
| Cell Differentiation | 2 | 2018 | 1338 | 0.24 | Why? |
| HLA-D Antigens | 1 | 2021 | 28 | 0.23 | Why? |
| Thyroid Neoplasms | 2 | 2017 | 422 | 0.23 | Why? |
| Mouth Neoplasms | 2 | 2018 | 463 | 0.23 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.22 | Why? |
| Butyrophenones | 1 | 2020 | 11 | 0.22 | Why? |
| Adaptor Proteins, Signal Transducing | 2 | 2018 | 502 | 0.22 | Why? |
| GTP Phosphohydrolases | 2 | 2019 | 89 | 0.21 | Why? |
| Dog Diseases | 1 | 2007 | 745 | 0.21 | Why? |
| Genomic Instability | 2 | 2018 | 80 | 0.21 | Why? |
| von Hippel-Lindau Disease | 1 | 2018 | 9 | 0.20 | Why? |
| Suburban Health | 1 | 2018 | 14 | 0.20 | Why? |
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2018 | 13 | 0.20 | Why? |
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2018 | 9 | 0.20 | Why? |
| Quinazolinones | 1 | 2020 | 135 | 0.19 | Why? |
| Suprachiasmatic Nucleus | 1 | 2018 | 6 | 0.19 | Why? |
| Biological Clocks | 1 | 2018 | 10 | 0.19 | Why? |
| Suburban Population | 1 | 2018 | 70 | 0.19 | Why? |
| Uterine Cervical Neoplasms | 2 | 2018 | 842 | 0.19 | Why? |
| Tumor Burden | 2 | 2017 | 369 | 0.18 | Why? |
| BRCA2 Protein | 1 | 2018 | 82 | 0.18 | Why? |
| ErbB Receptors | 2 | 2019 | 320 | 0.18 | Why? |
| Hepatitis Delta Virus | 1 | 2018 | 54 | 0.18 | Why? |
| Glycemic Load | 1 | 2017 | 9 | 0.18 | Why? |
| BRCA1 Protein | 1 | 2018 | 102 | 0.18 | Why? |
| Hepatitis D | 1 | 2018 | 48 | 0.18 | Why? |
| Telomerase | 1 | 2018 | 45 | 0.18 | Why? |
| Stearoyl-CoA Desaturase | 1 | 2017 | 13 | 0.18 | Why? |
| ras GTPase-Activating Proteins | 1 | 2017 | 4 | 0.18 | Why? |
| Therapeutic Touch | 1 | 2017 | 5 | 0.18 | Why? |
| Sepharose | 1 | 2017 | 12 | 0.18 | Why? |
| Adenosine Deaminase | 1 | 2018 | 85 | 0.18 | Why? |
| Thiadiazoles | 1 | 2017 | 15 | 0.18 | Why? |
| DNA Mutational Analysis | 2 | 2018 | 581 | 0.17 | Why? |
| Humans | 68 | 2021 | 930598 | 0.17 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1573 | 0.17 | Why? |
| Hemangiosarcoma | 1 | 2017 | 24 | 0.17 | Why? |
| Small Cell Lung Carcinoma | 1 | 2019 | 133 | 0.17 | Why? |
| Dietary Carbohydrates | 1 | 2017 | 64 | 0.17 | Why? |
| Cytoplasm | 1 | 2018 | 304 | 0.17 | Why? |
| Antineoplastic Agents, Phytogenic | 1 | 2019 | 183 | 0.17 | Why? |
| Chemoradiotherapy, Adjuvant | 1 | 2017 | 69 | 0.17 | Why? |
| Cervical Intraepithelial Neoplasia | 1 | 2018 | 114 | 0.16 | Why? |
| Celecoxib | 1 | 2017 | 49 | 0.16 | Why? |
| Pyridazines | 1 | 2017 | 86 | 0.16 | Why? |
| Paraffin Embedding | 1 | 2017 | 105 | 0.16 | Why? |
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 35 | 0.16 | Why? |
| Glycemic Index | 1 | 2017 | 115 | 0.16 | Why? |
| Ki-67 Antigen | 1 | 2017 | 139 | 0.16 | Why? |
| Human papillomavirus 16 | 1 | 2017 | 95 | 0.16 | Why? |
| Image Enhancement | 1 | 2018 | 177 | 0.16 | Why? |
| Hashimoto Disease | 1 | 2017 | 74 | 0.16 | Why? |
| Piperidines | 2 | 2020 | 795 | 0.16 | Why? |
| Triterpenes | 1 | 2019 | 199 | 0.16 | Why? |
| Carcinoma, Basal Cell | 1 | 2018 | 144 | 0.16 | Why? |
| Deoxycytidine | 1 | 2017 | 116 | 0.16 | Why? |
| Antimetabolites, Antineoplastic | 1 | 2017 | 99 | 0.16 | Why? |
| Biliary Tract Neoplasms | 1 | 2017 | 93 | 0.16 | Why? |
| Glioblastoma | 1 | 2019 | 187 | 0.16 | Why? |
| Doxorubicin | 1 | 2018 | 313 | 0.15 | Why? |
| Gene Regulatory Networks | 2 | 2018 | 820 | 0.15 | Why? |
| Cisplatin | 1 | 2017 | 209 | 0.15 | Why? |
| Nucleic Acids | 1 | 2021 | 435 | 0.15 | Why? |
| Ascitic Fluid | 1 | 2017 | 169 | 0.15 | Why? |
| In Situ Hybridization | 1 | 2017 | 390 | 0.15 | Why? |
| Oropharyngeal Neoplasms | 1 | 2017 | 138 | 0.15 | Why? |
| Neoplasm Grading | 1 | 2017 | 400 | 0.15 | Why? |
| Diabetes Mellitus | 2 | 2017 | 8207 | 0.15 | Why? |
| Italy | 11 | 2021 | 38444 | 0.15 | Why? |
| Aptamers, Nucleotide | 1 | 2018 | 265 | 0.15 | Why? |
| Myocytes, Cardiac | 2 | 2019 | 804 | 0.15 | Why? |
| Th17 Cells | 1 | 2020 | 657 | 0.14 | Why? |
| STAT3 Transcription Factor | 1 | 2017 | 268 | 0.14 | Why? |
| Tumor Suppressor Protein p53 | 1 | 2017 | 310 | 0.14 | Why? |
| Head and Neck Neoplasms | 2 | 2018 | 1568 | 0.14 | Why? |
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 372 | 0.14 | Why? |
| Purines | 1 | 2020 | 816 | 0.14 | Why? |
| Receptors, Urokinase Plasminogen Activator | 1 | 2017 | 252 | 0.14 | Why? |
| Tumor Cells, Cultured | 3 | 2019 | 254 | 0.14 | Why? |
| Female | 36 | 2021 | 380317 | 0.14 | Why? |
| Down-Regulation | 2 | 2018 | 1416 | 0.13 | Why? |
| Self Efficacy | 2 | 2017 | 717 | 0.13 | Why? |
| Pyridines | 2 | 2017 | 680 | 0.13 | Why? |
| Colitis | 1 | 2017 | 266 | 0.13 | Why? |
| Mouth Mucosa | 1 | 2017 | 323 | 0.13 | Why? |
| Cell Movement | 4 | 2018 | 695 | 0.13 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2018 | 724 | 0.13 | Why? |
| Complementary Therapies | 1 | 2017 | 280 | 0.13 | Why? |
| Sarcoma | 1 | 2017 | 290 | 0.13 | Why? |
| Lymph Nodes | 3 | 2018 | 1060 | 0.13 | Why? |
| Prognosis | 13 | 2019 | 32490 | 0.13 | Why? |
| Eye Neoplasms | 1 | 2014 | 71 | 0.13 | Why? |
| Neovascularization, Pathologic | 1 | 2017 | 305 | 0.13 | Why? |
| Disease Progression | 5 | 2018 | 13580 | 0.13 | Why? |
| Peptides | 2 | 2017 | 2513 | 0.12 | Why? |
| Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 896 | 0.12 | Why? |
| Curcumin | 1 | 2018 | 396 | 0.12 | Why? |
| Metabolome | 1 | 2017 | 624 | 0.12 | Why? |
| Disease-Free Survival | 1 | 2018 | 1654 | 0.12 | Why? |
| Drug Carriers | 1 | 2018 | 590 | 0.12 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.12 | Why? |
| Carcinoma, Ductal, Breast | 1 | 2013 | 149 | 0.12 | Why? |
| Fanconi Anemia Complementation Group Proteins | 1 | 2011 | 3 | 0.12 | Why? |
| Carcinoma, Renal Cell | 1 | 2018 | 545 | 0.12 | Why? |
| Anti-Inflammatory Agents | 3 | 2020 | 6153 | 0.11 | Why? |
| MutS Homolog 2 Protein | 1 | 2011 | 10 | 0.11 | Why? |
| Myeloid Cells | 1 | 2017 | 808 | 0.11 | Why? |
| Fanconi Anemia | 1 | 2011 | 15 | 0.11 | Why? |
| Aged | 22 | 2021 | 215776 | 0.11 | Why? |
| Antibodies, Monoclonal, Humanized | 4 | 2020 | 9335 | 0.11 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2018 | 830 | 0.11 | Why? |
| Survival Rate | 4 | 2019 | 9206 | 0.11 | Why? |
| RNA-Binding Proteins | 1 | 2018 | 1022 | 0.11 | Why? |
| Medical Informatics | 1 | 2018 | 648 | 0.11 | Why? |
| Middle Aged | 24 | 2021 | 270681 | 0.11 | Why? |
| Germ-Line Mutation | 1 | 2011 | 86 | 0.11 | Why? |
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 3633 | 0.11 | Why? |
| Cell Nucleus | 1 | 2013 | 399 | 0.11 | Why? |
| Urinary Bladder Neoplasms | 1 | 2017 | 614 | 0.11 | Why? |
| Biological Specimen Banks | 1 | 2018 | 1142 | 0.11 | Why? |
| Kaplan-Meier Estimate | 2 | 2017 | 4260 | 0.10 | Why? |
| Adaptation, Psychological | 3 | 2017 | 4996 | 0.10 | Why? |
| Extracellular Vesicles | 1 | 2017 | 607 | 0.10 | Why? |
| Colorectal Neoplasms | 2 | 2017 | 1884 | 0.10 | Why? |
| Membrane Proteins | 2 | 2019 | 1733 | 0.10 | Why? |
| Kidney Neoplasms | 1 | 2018 | 832 | 0.10 | Why? |
| Testicular Neoplasms | 1 | 2011 | 91 | 0.10 | Why? |
| Protein Kinase Inhibitors | 2 | 2017 | 1585 | 0.10 | Why? |
| Neoplasms, Germ Cell and Embryonal | 1 | 2011 | 106 | 0.10 | Why? |
| Pancreatic Neoplasms | 1 | 2017 | 609 | 0.10 | Why? |
| Nasal Mucosa | 1 | 2017 | 1218 | 0.10 | Why? |
| Liver Neoplasms | 2 | 2018 | 1666 | 0.10 | Why? |
| Inflammation | 3 | 2020 | 13255 | 0.09 | Why? |
| Intestinal Mucosa | 1 | 2017 | 1046 | 0.09 | Why? |
| Antineoplastic Agents | 5 | 2021 | 3550 | 0.09 | Why? |
| Lipid Peroxidation | 2 | 2019 | 114 | 0.09 | Why? |
| Adult | 22 | 2020 | 244371 | 0.09 | Why? |
| Killer Cells, Natural | 1 | 2018 | 2093 | 0.09 | Why? |
| Glycoproteins | 1 | 2013 | 615 | 0.09 | Why? |
| Papillomavirus Infections | 1 | 2017 | 861 | 0.09 | Why? |
| Male | 26 | 2021 | 367725 | 0.09 | Why? |
| Insulin | 1 | 2017 | 1316 | 0.09 | Why? |
| Nuclear Proteins | 1 | 2011 | 321 | 0.09 | Why? |
| Carcinoma, Hepatocellular | 1 | 2018 | 1222 | 0.09 | Why? |
| Gene Expression | 1 | 2018 | 3332 | 0.09 | Why? |
| Antigens, CD | 1 | 2013 | 984 | 0.09 | Why? |
| Xenograft Model Antitumor Assays | 2 | 2019 | 274 | 0.09 | Why? |
| Cell Shape | 1 | 2007 | 57 | 0.09 | Why? |
| Receptors, G-Protein-Coupled | 1 | 2011 | 309 | 0.09 | Why? |
| Interleukin-6 | 3 | 2020 | 7522 | 0.08 | Why? |
| Point-of-Care Systems | 1 | 2020 | 2955 | 0.08 | Why? |
| Sensitivity and Specificity | 5 | 2020 | 22971 | 0.08 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 1458 | 0.08 | Why? |
| Phenotype | 1 | 2018 | 4037 | 0.08 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.08 | Why? |
| Nanoparticles | 1 | 2018 | 2040 | 0.08 | Why? |
| Pyrazoles | 1 | 2017 | 1791 | 0.08 | Why? |
| Dietary Supplements | 1 | 2018 | 2251 | 0.08 | Why? |
| Quality of Life | 2 | 2017 | 9820 | 0.08 | Why? |
| Aged, 80 and over | 9 | 2020 | 88759 | 0.07 | Why? |
| Antirheumatic Agents | 1 | 2020 | 3023 | 0.07 | Why? |
| Neoplasm Invasiveness | 2 | 2018 | 582 | 0.07 | Why? |
| Rectum | 2 | 2018 | 495 | 0.07 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.07 | Why? |
| Gene Expression Regulation, Enzymologic | 2 | 2018 | 436 | 0.07 | Why? |
| Young Adult | 9 | 2017 | 93724 | 0.07 | Why? |
| Up-Regulation | 3 | 2018 | 2249 | 0.07 | Why? |
| Mice | 6 | 2019 | 21357 | 0.07 | Why? |
| Mast Cells | 1 | 2007 | 370 | 0.07 | Why? |
| Medical Oncology | 1 | 2020 | 3826 | 0.07 | Why? |
| Autoimmune Diseases | 1 | 2017 | 1996 | 0.06 | Why? |
| Stress, Psychological | 2 | 2017 | 10231 | 0.06 | Why? |
| Polymerase Chain Reaction | 1 | 2018 | 6740 | 0.06 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.06 | Why? |
| Treatment Outcome | 8 | 2020 | 51732 | 0.06 | Why? |
| Survival Analysis | 4 | 2017 | 7592 | 0.06 | Why? |
| Risk Factors | 5 | 2018 | 71621 | 0.06 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.06 | Why? |
| Animals | 10 | 2019 | 78931 | 0.06 | Why? |
| Immunophenotyping | 1 | 2007 | 1290 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.06 | Why? |
| Enzyme Inhibitors | 1 | 2013 | 1881 | 0.06 | Why? |
| Cell Survival | 2 | 2018 | 1581 | 0.06 | Why? |
| Palliative Care | 1 | 2017 | 2665 | 0.06 | Why? |
| Predictive Value of Tests | 3 | 2018 | 9537 | 0.06 | Why? |
| Antibodies, Monoclonal | 3 | 2017 | 8041 | 0.06 | Why? |
| Positron-Emission Tomography | 1 | 2007 | 802 | 0.06 | Why? |
| Heart Diseases | 1 | 2018 | 3503 | 0.05 | Why? |
| T-Lymphocytes | 1 | 2018 | 6670 | 0.05 | Why? |
| Adolescent | 5 | 2018 | 86841 | 0.05 | Why? |
| Thoracic Surgical Procedures | 1 | 2007 | 504 | 0.05 | Why? |
| Ultrasonography | 1 | 2017 | 4409 | 0.05 | Why? |
| Validation Studies as Topic | 1 | 2020 | 121 | 0.05 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2017 | 11367 | 0.05 | Why? |
| Boswellia | 1 | 2019 | 13 | 0.05 | Why? |
| Dogs | 1 | 2007 | 2529 | 0.05 | Why? |
| Protein Phosphatase 2 | 1 | 2018 | 18 | 0.05 | Why? |
| Chemokine CXCL12 | 1 | 2019 | 74 | 0.05 | Why? |
| Drug Evaluation | 1 | 2019 | 100 | 0.05 | Why? |
| Forkhead Box Protein O3 | 1 | 2018 | 30 | 0.05 | Why? |
| Leukotriene B4 | 1 | 2019 | 46 | 0.05 | Why? |
| Cytoprotection | 1 | 2018 | 44 | 0.05 | Why? |
| Tissue Array Analysis | 1 | 2018 | 75 | 0.05 | Why? |
| Hepatitis D, Chronic | 1 | 2018 | 16 | 0.05 | Why? |
| Specimen Handling | 1 | 2017 | 6190 | 0.05 | Why? |
| Transcription Factor RelA | 1 | 2019 | 122 | 0.05 | Why? |
| Pineal Gland | 1 | 2018 | 37 | 0.05 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.05 | Why? |
| Emulsions | 1 | 2018 | 80 | 0.05 | Why? |
| Antioxidants | 2 | 2019 | 1593 | 0.05 | Why? |
| CLOCK Proteins | 1 | 2018 | 24 | 0.05 | Why? |
| Jurkat Cells | 1 | 2018 | 273 | 0.05 | Why? |
| Viral Proteins | 1 | 2017 | 7370 | 0.04 | Why? |
| Subcellular Fractions | 1 | 2017 | 25 | 0.04 | Why? |
| Hazardous Waste Sites | 1 | 2017 | 4 | 0.04 | Why? |
| Government Agencies | 1 | 2020 | 248 | 0.04 | Why? |
| Azoxymethane | 1 | 2017 | 6 | 0.04 | Why? |
| Adenomatous Polyposis Coli Protein | 1 | 2017 | 15 | 0.04 | Why? |
| CA-19-9 Antigen | 1 | 2017 | 22 | 0.04 | Why? |
| Siloxanes | 1 | 2017 | 8 | 0.04 | Why? |
| Theranostic Nanomedicine | 1 | 2018 | 143 | 0.04 | Why? |
| Inhibitor of Apoptosis Proteins | 1 | 2017 | 21 | 0.04 | Why? |
| Lung | 1 | 2007 | 31049 | 0.04 | Why? |
| Dextran Sulfate | 1 | 2017 | 54 | 0.04 | Why? |
| Hyperinsulinism | 1 | 2017 | 27 | 0.04 | Why? |
| Receptors, Formyl Peptide | 1 | 2017 | 26 | 0.04 | Why? |
| Forkhead Transcription Factors | 1 | 2018 | 231 | 0.04 | Why? |
| Electrophoresis, Agar Gel | 1 | 2017 | 48 | 0.04 | Why? |
| Apoptosis | 2 | 2018 | 2335 | 0.04 | Why? |
| Molecular Imaging | 1 | 2018 | 110 | 0.04 | Why? |
| Axilla | 1 | 2018 | 198 | 0.04 | Why? |
| Pedigree | 1 | 2018 | 502 | 0.04 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2020 | 801 | 0.04 | Why? |
| DNA, Neoplasm | 1 | 2017 | 56 | 0.04 | Why? |
| Food Handling | 1 | 2017 | 103 | 0.04 | Why? |
| Optical Imaging | 1 | 2018 | 197 | 0.04 | Why? |
| Reproducibility of Results | 3 | 2018 | 11304 | 0.04 | Why? |
| Mediterranean Region | 1 | 2017 | 276 | 0.04 | Why? |
| Pyrimidinones | 1 | 2016 | 76 | 0.04 | Why? |
| Reference Standards | 1 | 2020 | 1163 | 0.04 | Why? |
| Administration, Intravenous | 1 | 2020 | 1115 | 0.04 | Why? |
| Protein Array Analysis | 1 | 2018 | 387 | 0.04 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.04 | Why? |
| Preoperative Period | 1 | 2017 | 271 | 0.04 | Why? |
| Drug Compounding | 1 | 2018 | 386 | 0.04 | Why? |
| Microsatellite Repeats | 1 | 2017 | 99 | 0.04 | Why? |
| Regional Blood Flow | 1 | 2017 | 172 | 0.04 | Why? |
| Antibody Affinity | 1 | 2021 | 1078 | 0.04 | Why? |
| Mutant Proteins | 1 | 2017 | 328 | 0.04 | Why? |
| Tomography, X-Ray Computed | 2 | 2017 | 25144 | 0.04 | Why? |
| Cardiotonic Agents | 1 | 2019 | 418 | 0.04 | Why? |
| Magnetite Nanoparticles | 1 | 2017 | 109 | 0.04 | Why? |
| Off-Label Use | 1 | 2020 | 553 | 0.04 | Why? |
| Chemoradiotherapy | 1 | 2018 | 362 | 0.04 | Why? |
| Light | 1 | 2018 | 306 | 0.04 | Why? |
| Systems Biology | 1 | 2018 | 320 | 0.04 | Why? |
| CTLA-4 Antigen | 1 | 2017 | 282 | 0.04 | Why? |
| Genetic Association Studies | 1 | 2018 | 559 | 0.04 | Why? |
| Repressor Proteins | 1 | 2017 | 232 | 0.04 | Why? |
| Genetic Loci | 1 | 2017 | 439 | 0.04 | Why? |
| Cardiotoxicity | 1 | 2018 | 365 | 0.04 | Why? |
| 3' Untranslated Regions | 1 | 2016 | 318 | 0.04 | Why? |
| Endoplasmic Reticulum Stress | 1 | 2017 | 253 | 0.04 | Why? |
| Perfusion Imaging | 1 | 2017 | 199 | 0.04 | Why? |
| HeLa Cells | 1 | 2018 | 1303 | 0.04 | Why? |
| Homeostasis | 1 | 2018 | 582 | 0.04 | Why? |
| AC133 Antigen | 1 | 2013 | 19 | 0.03 | Why? |
| Logistic Models | 2 | 2021 | 9089 | 0.03 | Why? |
| Promoter Regions, Genetic | 1 | 2018 | 823 | 0.03 | Why? |
| Case-Control Studies | 3 | 2017 | 17671 | 0.03 | Why? |
| Bilirubin | 1 | 2017 | 503 | 0.03 | Why? |
| Benzamides | 1 | 2017 | 421 | 0.03 | Why? |
| Ipilimumab | 1 | 2014 | 102 | 0.03 | Why? |
| Energy Metabolism | 1 | 2018 | 451 | 0.03 | Why? |
| Prospective Studies | 4 | 2020 | 43301 | 0.03 | Why? |
| Risk Assessment | 1 | 2018 | 25439 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2020 | 2324 | 0.03 | Why? |
| Retina | 1 | 2018 | 424 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2020 | 2437 | 0.03 | Why? |
| Particle Size | 1 | 2018 | 1052 | 0.03 | Why? |
| Remission Induction | 1 | 2017 | 950 | 0.03 | Why? |
| Interleukin-8 | 1 | 2019 | 964 | 0.03 | Why? |
| Reactive Oxygen Species | 1 | 2019 | 1136 | 0.03 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2017 | 782 | 0.03 | Why? |
| Multimodal Imaging | 1 | 2017 | 534 | 0.03 | Why? |
| Limit of Detection | 1 | 2020 | 2698 | 0.03 | Why? |
| Drug Monitoring | 1 | 2020 | 1408 | 0.03 | Why? |
| Mastectomy | 1 | 2017 | 536 | 0.03 | Why? |
| Diagnosis, Differential | 1 | 2007 | 7220 | 0.03 | Why? |
| Carcinoma, Embryonal | 1 | 2011 | 1 | 0.03 | Why? |
| Thiazoles | 1 | 2017 | 496 | 0.03 | Why? |
| MutL Protein Homolog 1 | 1 | 2011 | 8 | 0.03 | Why? |
| T-Lymphocytes, Regulatory | 1 | 2018 | 698 | 0.03 | Why? |
| Seminoma | 1 | 2011 | 16 | 0.03 | Why? |
| Early Diagnosis | 1 | 2020 | 2443 | 0.03 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.03 | Why? |
| Radiopharmaceuticals | 1 | 2017 | 763 | 0.03 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.03 | Why? |
| Teratoma | 1 | 2011 | 25 | 0.03 | Why? |
| Gene Expression Regulation, Viral | 1 | 2017 | 925 | 0.03 | Why? |
| Melatonin | 1 | 2018 | 578 | 0.03 | Why? |
| Cohort Studies | 3 | 2020 | 36005 | 0.03 | Why? |
| Educational Status | 1 | 2017 | 1451 | 0.03 | Why? |
| DNA Repair | 1 | 2011 | 114 | 0.03 | Why? |
| Rats | 1 | 2018 | 2764 | 0.03 | Why? |
| Pyridones | 1 | 2016 | 738 | 0.03 | Why? |
| Models, Biological | 2 | 2018 | 4907 | 0.03 | Why? |
| Whole Genome Sequencing | 1 | 2021 | 3239 | 0.03 | Why? |
| Follow-Up Studies | 2 | 2019 | 17020 | 0.03 | Why? |
| Cell Transformation, Neoplastic | 1 | 2011 | 191 | 0.02 | Why? |
| Digestive System Surgical Procedures | 1 | 2017 | 677 | 0.02 | Why? |
| Area Under Curve | 1 | 2017 | 2564 | 0.02 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2017 | 1153 | 0.02 | Why? |
| Immunoenzyme Techniques | 1 | 2011 | 448 | 0.02 | Why? |
| Image Processing, Computer-Assisted | 1 | 2017 | 1383 | 0.02 | Why? |
| Base Sequence | 1 | 2016 | 3581 | 0.02 | Why? |
| Indoles | 1 | 2016 | 1243 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.02 | Why? |
| Sulfonamides | 1 | 2016 | 1294 | 0.02 | Why? |
| Fatal Outcome | 1 | 2017 | 3438 | 0.02 | Why? |
| Cells, Cultured | 1 | 2018 | 5835 | 0.02 | Why? |
| Oxidative Stress | 1 | 2018 | 2050 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Chromatography, High Pressure Liquid | 1 | 2011 | 669 | 0.02 | Why? |
| Inflammation Mediators | 1 | 2018 | 2654 | 0.02 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.02 | Why? |
| Environmental Exposure | 1 | 2017 | 1558 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2017 | 3788 | 0.02 | Why? |
| Diet | 1 | 2017 | 2052 | 0.02 | Why? |
| Diabetes Complications | 1 | 2017 | 2358 | 0.02 | Why? |
| Flow Cytometry | 1 | 2013 | 2393 | 0.02 | Why? |
| Epithelial Cells | 1 | 2017 | 3508 | 0.02 | Why? |
| Prostatic Neoplasms | 1 | 2017 | 1637 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| RNA, Messenger | 1 | 2018 | 5131 | 0.02 | Why? |
| Biopsy | 1 | 2013 | 2811 | 0.02 | Why? |
| Immunologic Factors | 1 | 2020 | 4206 | 0.02 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.02 | Why? |
| Molecular Dynamics Simulation | 1 | 2017 | 4155 | 0.02 | Why? |
| Binding Sites | 1 | 2016 | 6201 | 0.02 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| Blood Glucose | 1 | 2017 | 3642 | 0.02 | Why? |
| Computational Biology | 1 | 2018 | 4514 | 0.02 | Why? |
| Cell Line | 1 | 2018 | 12040 | 0.02 | Why? |
| Multiple Sclerosis | 1 | 2018 | 2600 | 0.02 | Why? |
| Protein Binding | 1 | 2018 | 11430 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2018 | 10998 | 0.01 | Why? |
| Signal Transduction | 1 | 2017 | 7207 | 0.01 | Why? |
| Immunity, Innate | 1 | 2018 | 6570 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.01 | Why? |
| Drug Design | 1 | 2011 | 2627 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2017 | 10649 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Obesity | 1 | 2017 | 7388 | 0.01 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.01 | Why? |
| Cytokines | 1 | 2018 | 15010 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| China | 1 | 2021 | 50654 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2021 | 27595 | 0.01 | Why? |
| Anxiety | 1 | 2017 | 17311 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.01 | Why? |
| Child | 1 | 2017 | 70012 | 0.01 | Why? |